Abstract：
BACKGROUND: We investigated the link between habitual caffeine intake with memory impairments and cerebrospinal fluid (CSF) biomarkers in mild cognitive impairment (MCI) and Alzheimer\'s disease (AD) patients.
METHODS: MCI (N = 147) and AD (N = 116) patients of the Biomarker of AmyLoid pepTide and AlZheimer\'s diseAse Risk (BALTAZAR) cohort reported their caffeine intake at inclusion using a dedicated survey. Associations of caffeine consumption with memory impairments and CSF biomarkers (tau, p-tau181, amyloid beta 1-42 [Aβ1-42], Aβ1-40) were analyzed using logistic and analysis of covariance models.
RESULTS: Adjusted on Apolipoprotein E (APOE ε4), age, sex, education level, and tobacco, lower caffeine consumption was associated with higher risk to be amnestic (OR: 2.49 [95% CI: 1.13 to 5.46]; p = 0.023) and lower CSF Aβ1-42 (p = 0.047), Aβ1-42/Aβ1-40 (p = 0.040), and Aβ1-42/p-tau181 (p = 0.020) in the whole cohort.
CONCLUSIONS: Data support the beneficial effect of caffeine consumption to memory impairments and CSF amyloid markers in MCI and AD patients.
CONCLUSIONS: We studied the impact of caffeine consumption in the BALTAZAR cohort. Low caffeine intake is associated with higher risk of being amnestic in MCI/AD patients. Caffeine intake is associated with CSF biomarkers in AD patients.
METHODS: MCI (N = 147) and AD (N = 116) patients of the Biomarker of AmyLoid pepTide and AlZheimer\'s diseAse Risk (BALTAZAR) cohort reported their caffeine intake at inclusion using a dedicated survey. Associations of caffeine consumption with memory impairments and CSF biomarkers (tau, p-tau181, amyloid beta 1-42 [Aβ1-42], Aβ1-40) were analyzed using logistic and analysis of covariance models.
RESULTS: Adjusted on Apolipoprotein E (APOE ε4), age, sex, education level, and tobacco, lower caffeine consumption was associated with higher risk to be amnestic (OR: 2.49 [95% CI: 1.13 to 5.46]; p = 0.023) and lower CSF Aβ1-42 (p = 0.047), Aβ1-42/Aβ1-40 (p = 0.040), and Aβ1-42/p-tau181 (p = 0.020) in the whole cohort.
CONCLUSIONS: Data support the beneficial effect of caffeine consumption to memory impairments and CSF amyloid markers in MCI and AD patients.
CONCLUSIONS: We studied the impact of caffeine consumption in the BALTAZAR cohort. Low caffeine intake is associated with higher risk of being amnestic in MCI/AD patients. Caffeine intake is associated with CSF biomarkers in AD patients.
摘要：
背景：我们研究了轻度认知障碍（MCI）和阿尔茨海默病（AD）患者习惯性摄入咖啡因与记忆障碍和脑脊液（CSF）生物标志物之间的联系。
方法：AmyloidpepTide生物标志物和AlZheimer病酶风险（BALTAZAR）队列的MCI（N=147）和AD（N=116）患者报告了他们在纳入时的咖啡因摄入量。咖啡因消费与记忆障碍和CSF生物标志物的关系(tau，p-tau181，淀粉样蛋白β1-42[Aβ1-42]，Aβ1-40)采用logistic和协方差模型分析。
结果：对载脂蛋白E（APOEε4）进行调整，年龄,性别,教育水平,烟草,较低的咖啡因摄入量与较高的遗忘风险相关（OR：2.49[95％CI：1.13至5.46]；p=0.023）和较低的CSFAβ1-42（p=0.047），Aβ1-42/Aβ1-40(p=0.040),和Aβ1-42/p-tau181(p=0.020)在整个队列中。
结论：数据支持咖啡因摄入对MCI和AD患者记忆障碍和CSF淀粉样蛋白标志物的有益作用。
结论：我们在BALTAZAR队列中研究了咖啡因消费的影响。在MCI/AD患者中，低咖啡因摄入与更高的遗忘风险相关。咖啡因摄入与AD患者的CSF生物标志物相关。
方法：AmyloidpepTide生物标志物和AlZheimer病酶风险（BALTAZAR）队列的MCI（N=147）和AD（N=116）患者报告了他们在纳入时的咖啡因摄入量。咖啡因消费与记忆障碍和CSF生物标志物的关系(tau，p-tau181，淀粉样蛋白β1-42[Aβ1-42]，Aβ1-40)采用logistic和协方差模型分析。
结果：对载脂蛋白E（APOEε4）进行调整，年龄,性别,教育水平,烟草,较低的咖啡因摄入量与较高的遗忘风险相关（OR：2.49[95％CI：1.13至5.46]；p=0.023）和较低的CSFAβ1-42（p=0.047），Aβ1-42/Aβ1-40(p=0.040),和Aβ1-42/p-tau181(p=0.020)在整个队列中。
结论：数据支持咖啡因摄入对MCI和AD患者记忆障碍和CSF淀粉样蛋白标志物的有益作用。
结论：我们在BALTAZAR队列中研究了咖啡因消费的影响。在MCI/AD患者中，低咖啡因摄入与更高的遗忘风险相关。咖啡因摄入与AD患者的CSF生物标志物相关。
